The list of Saxenda contraindications includes just a few diseases and conditions. Saxenda slimming drug should not be prescribed to overweight and obese men and women with:
• multiple endocrine neoplasia type 2 (MEN 2)
• medullary thyroid cancer (MTC) or family history of MTC
• allergy to anorexigenic agent – Liraglutide or inactive ingredients of Saxenda.
Children, adolescents under 18 years and pregnant women did not participate in clinical trials of Saxenda. Therefore, these groups of patients should be prescribed with alternative drugs for the obesity treatment instead of Saxenda.
Besides the list of contraindications, Product Monograph (Highlights of Prescribing Information) for Saxenda includes the list of cautions.
Saxenda injections should not be prescribed to patients, who are taking or planning to take other drugs included in the pharmacological group of glucagon-like peptide-1 (GLP-1) receptor agonists, such as:
• Albiglutide (Eperzan)
• Dulaglutide (Trulicity)
• Lixisenatide (Lyxumia)
• Exenatide (Bydureon, Byetta)
Moreover, Saxenda should not be used in the combination with insulin and other prescription or over-the-counter weight loss products.
If inflammation of pancreas occurred and pancreatitis was diagnosed during medical therapy of obesity, Saxenda use should be stopped. The main symptom of pancreatitis is severe abdominal pain.
Saxenda can cause a significant reduction of blood sugar level. Therefore, after the monitoring of blood glucose parameters, diabetic patients taking Saxenda may require the adjustment of daily doses of hypoglycemic drugs.
Some patients using Saxenda may develop gallstone disease. Data of clinical studies is insufficient to claim that gallstone disease is caused by Saxenda.
Nevertheless, if problems with gall bladder or bile ducts occur, it is necessary to stop using Saxenda and diagnose the cause of gallstone disease symptoms.
During clinical studies, it was recorded individual cases of thyroid cancer. However, a causal relationship between Saxenda use and thyroid cancer was not established. Nevertheless, the signs of thyroid cancer require an immediate cancellation of Saxenda. The main signs of thyroid cancer are increase in the size and mass of the neck, hoarseness, reduction in the frequency and depth of breathing, inflammation of the esophagus.
Saxenda may cause a slight increase in heart rate. Thus, obese patients with tachycardia require a regular monitoring of heart rate after the start of Saxenda use.
Saxenda can affect kidney functions. Therefore, patients with renal insufficiency should take Saxenda with caution.
In 0.2 % obese patients, treated with Saxenda during clinical studies, had suicidal thoughts and signs of depression. If unusual behavior or signs of anxiety disorder are observed after the start of Saxenda use, be sure to inform your treating physician.